NASDAQ NMS - GLOBAL MARKET · NAMS
-0.47% · -$0.1300 · Vol 1.5M
After hours · updated 16:00:16 ET
NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company NV

Biotechnology
$27.42
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
NAMS
NewAmsterdam Pharma Company NV
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

47/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NAMS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NAMS catalysts
About NewAmsterdam Pharma Company NV
PHARMACEUTICAL PREPARATIONS
Listed since
2022
Employees
100
Country
NL

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$27.33
Day high
$27.84
Day low
$25.74
Previous close
$27.55
52W high
$41.45
-33.85% from high
52W low
$21.73
29% of range
Market cap
$3.2B
EPS
$-1.5000
Beta
1.17
Shares out
116.9M
Volume
1.5M
1.49× rel vol
Avg volume
1M
VWAP
$27.05
Price history computed in-house
1W
-1.76%
1M
-21.43%
3M
-21.32%
1Y
+26.18%
YTD
-21.84%
SMA 50 $31.96 · below
SMA 200 $33.73 · below
52W position 29%

NAMS overview

Veridion Score
47
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NAMS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NAMS Form 4 filings
Public disclosures

Congress activity in NAMS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NAMS in the cached public ledger.

Federal contracts

NAMS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NAMS in this window.
Lobbying spend

NAMS lobbying filings, year to date.

Registered lobbying filings matched to NewAmsterdam Pharma Company NV.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NAMS in this window.
Loading news for NAMS
Analyst ratings
Sovereign unlock shows live analyst consensus for NAMS.
Options
Sovereign unlock shows live options positioning for NAMS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.